UB Paderborn / Katalog / Suche / in CDI

PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP

Hematological oncology, 2019-06, Vol.37 (S2), p.296-298

2019

Link zum Volltext

Verfügbarkeit prüfen

HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

A systematic review of contemporary phase I trials in patients with lymphoma

Critical reviews in oncology/hematology, 2022-12, Vol.180, p.103860-103860, Article 103860

2022

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Annals of oncology, 2018-03, Vol.29 (3), p.707-714

2018

Link zum Volltext

Verfügbarkeit prüfen

Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2020-05, Vol.55 (5), p.918-928

2020

Link zum Volltext

Verfügbarkeit prüfen

The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD

Bone marrow transplantation (Basingstoke), 2014-12, Vol.49 (12), p.1528-1534

2014

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

Bone marrow transplantation (Basingstoke), 2014-09, Vol.49 (9), p.1162-1169

2014

Link zum Volltext

Verfügbarkeit prüfen

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients

Clinical microbiology and infection, 2018-06, Vol.24 (6), p.640-645

2018

Link zum Volltext

Verfügbarkeit prüfen

Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT

Bone marrow transplantation (Basingstoke), 2013-08, Vol.48 (8), p.1104-1111

2013

Link zum Volltext

Verfügbarkeit prüfen

Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation

Annals of oncology, 2013-06, Vol.24 (6), p.1603-1609

2013

Link zum Volltext

Verfügbarkeit prüfen

PHASE I STUDY OF THE CD19/CD3 HALF‐LIFE EXTENDED BITE ® MOLECULE AMG 562 IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2

Bone marrow transplantation (Basingstoke), 2015-11, Vol.50 (11), p.1405-1410

2015

Link zum Volltext

Verfügbarkeit prüfen

Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2016-06, Vol.51 (6), p.841-847

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission

Bone marrow transplantation (Basingstoke), 2015-07, Vol.50 (7), p.907-913

2015

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation

Bone marrow transplantation (Basingstoke), 2015-09, Vol.50 (9), p.1180-1186

2015

Link zum Volltext

Verfügbarkeit prüfen

A FIRST‐IN‐HUMAN STUDY OF A HALF‐LIFE EXTENDED CD19‐TARGETING BiTE IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA OR FOLLICULAR LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.566-567

2019

Link zum Volltext

Verfügbarkeit prüfen

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMA

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

FUNCTIONAL PREDICTORS OF CHEMOTHERAPY TOXICITY IN ELDERLY LYMPHOMA PATIENTS – A PROSPECTIVE PILOT STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.541-542

2019

Link zum Volltext

Verfügbarkeit prüfen

A PHASE II STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

PRIMARY CENTRAL NERVOUS SYSTEM POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (CNS‐PTLD): A 20 YEARS RETROSPECTIVE SINGLE CENTER EXPERIENCE

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

Autologous Infant and Allogeneic Adult Red Cells Demonstrate Similar Concurrent Post-Transfusion Survival in Very Low Birth Weight Neonates

The Journal of pediatrics, 2015-11, Vol.167 (5), p.1001-1006

2015

Link zum Volltext

Verfügbarkeit prüfen

A Method to Evaluate Fetal Erythropoiesis from Postnatal Survival of Fetal RBCs

The AAPS journal, 2015-09, Vol.17 (5), p.1246-1254

2015

Link zum Volltext

Verfügbarkeit prüfen

NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP

HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN

A systematic review of contemporary phase I trials in patients with lymphoma

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation

The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients

Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT

Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation

PHASE I STUDY OF THE CD19/CD3 HALF‐LIFE EXTENDED BITE ® MOLECULE AMG 562 IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA

Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2

Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation

Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission

Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation

A FIRST‐IN‐HUMAN STUDY OF A HALF‐LIFE EXTENDED CD19‐TARGETING BiTE IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA OR FOLLICULAR LYMPHOMA

NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMA

FUNCTIONAL PREDICTORS OF CHEMOTHERAPY TOXICITY IN ELDERLY LYMPHOMA PATIENTS – A PROSPECTIVE PILOT STUDY

A PHASE II STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA

PRIMARY CENTRAL NERVOUS SYSTEM POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (CNS‐PTLD): A 20 YEARS RETROSPECTIVE SINGLE CENTER EXPERIENCE

A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS

Autologous Infant and Allogeneic Adult Red Cells Demonstrate Similar Concurrent Post-Transfusion Survival in Very Low Birth Weight Neonates

A Method to Evaluate Fetal Erythropoiesis from Postnatal Survival of Fetal RBCs

NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

Suchergebnisse filtern